Aug. 19 at 1:30 PM
$IVVD The path to
$10 🤑
The Validation Multiplier: Success across two distinct indications (COVID-19 with VYD2311 and RSV with VBY329) mathematically proves that the INVYMAB engine is not a fluke. Wall Street stops valuing Invivyd on basic product sales and begins applying a "platform premium," heavily boosting the multiple.
The Partnership Financial Cushion: A major biotech partnership typically includes a large upfront cash payment (
$100M–
$300M) and milestone bonuses. This cash injection immediately eliminates the threat of predatory share dilution, protecting the share structure and allowing the PPS to rise cleanly alongside the market cap.
Commercial De-risking: Big Pharma brings global distribution infrastructure. A partnership removes the risk of Invivyd failing to sell the drugs themselves, guaranteeing institutional investors a clear path to high-margin royalty revenue.
